ALT5 Sigma Corp (ALTS)·Q4 2024 Earnings Summary

Executive Summary

• ALT5 Sigma delivered a record Q4 with Fintech revenue of $5.42M, capped by full-year Fintech revenue of $12.53M and a 50.2% Fintech gross margin, while surpassing 1,000 customers; management emphasized sustained growth and scalability, supported by leadership additions and product expansion .
• Non-GAAP Adjusted EBITDA for the Fintech segment was approximately $1.03M in Q4 and 18.2% for FY 2024, even as consolidated GAAP EBITDA and net income remained negative; the divergence underscores non-GAAP adjustments and segment vs consolidated dynamics .
• Working capital improved by $4.5M from Q3 to Q4 and cash ended Q4 at $7.18M, reflecting balance sheet progress despite investment and integration activity .
• Strategic catalysts included appointment of a COO, new crypto pairs (including merchant acceptance of $TRUMP Coin), Odoo integration (announced post year-end), and continued progress toward separating Alyea Therapeutics for a standalone listing—key narratives likely to drive investor focus on execution and monetization .

What Went Well and What Went Wrong

What Went Well

• Record Q4 Fintech revenue ($5.42M) following a record Q3 ($4.94M), highlighting sequential momentum; CEO: “another record-breaking quarter… we are firmly positioned for sustained growth” .
• Scale and customer traction: “Customer Base Surpasses 1,000 Accounts,” and ALT5 processed over $2B in crypto transactions in 2024, validating market engagement and platform relevance .
• Strengthened organization and ecosystem: appointment of Ron Pitters as COO; post year-end integration with Odoo’s POS/eCommerce/ERP stack to expand addressable reach and merchant capability .

What Went Wrong

• Consolidated GAAP profitability remained negative in Q4 despite strong segment non-GAAP results, signaling continued corporate-level drag from non-Fintech items and/or consolidation effects; consolidated metrics show negative EBITDA and net income * (Values retrieved from S&P Global).
• Cash declined sequentially from $8.67M in Q3 to $7.18M in Q4, while investments and integration continued; investors should monitor cash conversion in 2025 .
• Limited visibility on formal numerical guidance (revenue, margins, EPS) and absence of an earnings call transcript constrains near-term estimate anchoring and narrative calibration for the Street .

Financial Results

Consolidated Results (GAAP)

Notes:

• Consolidated GAAP figures may include non-Fintech items and acquisition accounting effects; Fintech segment results are presented separately below .

Balance Sheet Snapshot

Management disclosed a working capital improvement of $4.5M from Q3 to Q4, consistent with the S&P Global figures above .

Fintech Segment Results and KPIs

Comparability note: Fintech results in FY 2024 include operations from May 15, 2024 onward due to acquisition timing .

Guidance Changes

No numerical guidance ranges were provided in the documents reviewed; management emphasized growth trajectory and strategic initiatives rather than formal targets .

Earnings Call Themes & Trends

No Q4 2024 earnings call transcript was found in the document catalog. Themes below reflect management commentary from Q3 and Q4 press releases.

Management Commentary

• CEO: “ALT5 Sigma’s Fintech segment delivered outstanding performance in Q4… we are firmly positioned for sustained growth… having achieved the on-boarding of over 1,000 customers… we are excited about the future, focused on scaling our operations” .
• Strategic focus: “We continue to see strong demand… significant customer onboarding and deeper engagements… expanding our services and preparing for geographic growth” (Q3 commentary framing the trajectory into Q4/FY25) .
• Organizational evolution: “We are making significant progress in the… separation of our biotech business… enabling biotech investors to focus on the biotech business… leveraging fintech’s future free cash flow” .
• Leadership addition: “We are thrilled to welcome Ron… his vast experience and strategic vision will be instrumental in scaling ALT5 to new heights” .

Q&A Highlights

No Q4 2024 earnings call transcript or Q&A was available in the document catalog; therefore, no analyst Q&A themes or clarifications could be extracted .

Estimates Context

• Consensus availability was limited; we found no Street quarterly consensus for revenue, EPS, or EBITDA to anchor beats/misses for Q4 2024. Target price datapoints were sparse (single estimate) and not period-specific in a way that informs quarterly surprises [GetEstimates]* (Values retrieved from S&P Global).
• Without formal numerical guidance from management and lacking quarterly consensus, estimate recalibration likely hinges on updated coverage post-segmentation progress and Fintech scaling disclosures .

Key Takeaways for Investors

• Sequential Fintech revenue momentum (Q3: $4.94M → Q4: $5.42M) with 50.2% FY Fintech gross margin and positive adjusted EBITDA indicates operational strength within the segment, even as consolidated GAAP remains loss-making—focus on segment vs consolidated economics .
• Balance sheet improvement (working capital +$4.5M Q/Q) and still-healthy cash ($7.18M) provide near-term flexibility to invest in product and GTM, but cash conversion and consolidated profitability remain key watch items into 2025 .
• Customer scale milestone (1,000+) and processed volume ($2B in 2024) support network effects and transaction-driven revenue durability; monitor merchant adoption of ALT5 Pay, new pairs, and Odoo-linked expansion for incremental runway .
• Corporate actions are a catalyst: COO appointment, IP portfolio bolstering, and progressed Alyea separation could unlock valuation clarity by isolating Fintech cash flows from biotech development timelines .
• Near-term trading implications: absent quarterly consensus and formal guidance, narrative catalysts (integration updates, awards, customer growth) may drive sentiment; watch for subsequent filings to quantify FY25 trajectory and margin mix .
• Medium-term thesis: scaling payments/trading platforms with demonstrated gross margins and adjusted EBITDA leverage; execution focus on merchant onboarding, geographic expansion, and product innovation vs. consolidated GAAP normalization .

---

Sources:

• Q4 2024 8-K Item 2.02 press release and exhibit: ALT5 Sigma Reports Strong Q4 and Full-Year 2024 Results .
• Q3 2024 8-K Item 2.02 press release: ALT5 Sigma Reports Fiscal Financial Results for Third Quarter 2024 .
• Company description and platform details, transaction volume, and segment strategy .

Estimate data:

• S&P Global data retrieved via GetEstimates; limited availability and coverage for quarterly consensus. Values marked with an asterisk are “Values retrieved from S&P Global.”